Treace to Present at 43rd Annual J.P. Morgan Healthcare Conference
Treace Medical Concepts (NasdaqGS: TMCI), a pioneer in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
CEO John T. Treace will deliver a presentation on Tuesday, January 14, 2025, at 9:00 am PT. The company will provide a live webcast of the fireside chat, which will be accessible through their investor relations website at https://investors.treace.com/.
The company maintains regular updates for investors through their website's Investor Relations section at www.treace.com, where important information is routinely posted for stakeholders and potential investors.
Treace Medical Concepts (NasdaqGS: TMCI), un pioniere nei trattamenti chirurgici per le deformità del alluce valgo e del mesopiede attraverso le sue Procedure Lapiplasty® e Adductoplasty®, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan.
Il CEO John T. Treace presenterà il suo intervento martedì 14 gennaio 2025, alle 9:00 PST. L'azienda fornirà una diretta streaming della chiacchierata, che sarà accessibile attraverso il loro sito web per le relazioni con gli investitori all'indirizzo https://investors.treace.com/.
L'azienda mantiene aggiornamenti regolari per gli investitori attraverso la sezione Relazioni con gli Investitori del sito web www.treace.com, dove informazioni importanti vengono pubblicate regolarmente per gli stakeholder e i potenziali investitori.
Treace Medical Concepts (NasdaqGS: TMCI), un pionero en tratamientos quirúrgicos para las deformidades del juanete y del mediopie a través de sus Procedimientos Lapiplasty® y Adductoplasty®, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan.
El CEO John T. Treace hará una presentación el martes 14 de enero de 2025, a las 9:00 am PT. La empresa ofrecerá una transmisión en vivo de la charla, que será accesible a través de su sitio web de relaciones con inversores en https://investors.treace.com/.
La empresa mantiene actualizaciones regulares para los inversores a través de la sección de Relaciones con Inversores de su sitio web www.treace.com, donde se publica información importante de manera rutinaria para las partes interesadas y los inversores potenciales.
트리체 메디컬 컨셉츠 (NasdaqGS: TMCI)는 라피플라스티® 및 어덕토플라스티® 절차를 통해 만곡성 수술 치료의 선구자입니다. 최근 제43회 JP 모건 헬스케어 컨퍼런스 참여를 발표했습니다.
CEO 존 T. 트리체는 2025년 1월 14일 화요일, 오전 9시 PT에 발표를 진행할 예정입니다. 회사는 화재 대화의 생중계를 제공할 것이며, 이는 투자자 관계 웹사이트인 https://investors.treace.com/를 통해 접근 가능합니다.
회사는 www.treace.com의 투자자 관계 섹션을 통해 투자자들에게 정기적으로 업데이트를 제공하며, 이해관계자 및 잠재적 투자자를 위한 중요한 정보가 정기적으로 게시됩니다.
Treace Medical Concepts (NasdaqGS: TMCI), un pionnier dans les traitements chirurgicaux des déformations des oignons et du medio-pied grâce à ses procédures Lapiplasty® et Adductoplasty®, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé.
Le PDG John T. Treace fera une présentation mardi 14 janvier 2025, à 9h00 PT. L'entreprise proposera un webinaire en direct de la discussion qui sera accessible via leur site Web de relations investisseurs à l'adresse https://investors.treace.com/.
La société maintient des mises à jour régulières pour les investisseurs via la section Relations Investisseurs de son site Web www.treace.com, où des informations importantes sont régulièrement publiées pour les parties prenantes et les investisseurs potentiels.
Treace Medical Concepts (NasdaqGS: TMCI), ein Pionier in der chirurgischen Behandlung von Hallux-Valgus- und Mittelfußdeformitäten durch seine Lapiplasty®- und Adductoplasty®-Verfahren, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben.
CEO John T. Treace wird am Dienstag, den 14. Januar 2025, um 9:00 Uhr PT eine Präsentation halten. Das Unternehmen wird ein Live-Webcast des Fireside Chats bereitstellen, der über ihre Investor-Relations-Website unter https://investors.treace.com/ zugänglich sein wird.
Das Unternehmen hält regelmäßige Updates für Investoren über den Bereich Investor Relations auf der Website www.treace.com bereit, wo wichtige Informationen routinemäßig für Anleger und potenzielle Investoren veröffentlicht werden.
- None.
- None.
PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When is Treace Medical Concepts (TMCI) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Treace Medical's (TMCI) J.P. Morgan Healthcare Conference presentation?
What surgical procedures does Treace Medical (TMCI) specialize in?
Where can investors find important information about Treace Medical (TMCI)?
